EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial

Aiden V Brossfield, Donald J McMahon, Jason Fernando, Beatriz Omeragic, Rukshana Majeed, Sanchita Agarwal iD, Grazyna E Sroga, Bowen Wang iD, Deepak Vashishth iD, Mishaela R Rubin iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae700 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Aiden V Brossfield und 9 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Bone Disease Unit, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycation End Products, Advanced, Pyridoxamine, Bone and Bones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: NIH/NIA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Patients with type 2 diabetes (T2D) have reduced bone turnover and increased fractures. Advanced glycation end products (AGEs) impair osteoblasts and are implicated in diabetic fractures. Pyridoxamine (PM) is a vitamin B6 metabolite that inhibits formation of AGEs.

Objective

We hypothesized that PM treatment in older patients with T2D, by inhibiting AGEs, would increase bone formation.

Methods

This was a double-blind randomized controlled trial at an academic center. Older women with T2D were included (n = 55). Oral PM 200 mg twice daily for 1 year was given. The primary outcome was the change in the bone formation marker P1NP. Other outcomes were changes in bone resorption, bone mineral density (BMD), HbA1c, and skin autofluorescence (SAF), and in a bone biopsy subgroup, the correlation between bone fluorescent AGEs (fAGEs) and SAF.

Results

P1NP increased 23.0% with PM (95% CI 9, 37; within group P = .028) vs 4.1% with placebo (−9, 17; within group P = .576; between groups P = .056). BMD increased at the femoral neck (PM 2.6 ± 5% vs placebo −0.9 ± 4%; between groups P = .007). Bone resorption markers and SAF did not change. HbA1c decreased (PM −0.38 ± 0.7% vs placebo 0.05 ± 1.7%; between groups P = .04). Within the PM group, the HbA1c change correlated inversely with the % P1NP change (r = −0.50, P = .034). Cortical bone biopsy fAGEs correlated with SAF (r = 0.86, P = .001). Adverse events were similar between groups.

Conclusion

PM tended to increase P1NP in older women with T2D, as well as increasing bone density and reducing HbA1c. Further studies are needed to investigate the potential of PM as a disease mechanism–directed approach to reduce fractures in T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycation End Products, AdvancedPyridoxamineBone and BonesHumansFemaleAgedDouble-Blind MethodBone DensityMiddle AgedGlycated HemoglobinOsteogenesisBone RemodelingProcollagenBiomarkersPeptide Fragments

Stichwörter der Autor:innen

advanced glycation end productsbone formationpyridoxaminetype 2 diabetes

Substanzen

Glycation End Products, AdvancedPyridoxamineGlycated Hemoglobinprocollagen Type I N-terminal peptideProcollagenBiomarkersPeptide Fragments

Autor:innen und Institutionen

  • Metabolic Bone Disease Unit, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Department of Biomedical Engineering, Shirley Ann Jackson, PhD Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
  • Rensselaer-Icahn School of Medicine Center for Engineering and Precision Medicine, New York, NY 10029, USA.

ORCID-Profile: Sanchita Agarwal, Bowen Wang, Deepak Vashishth, Mishaela R Rubin

Förderung

  • NIH/NIA

Zitieren

APA

Brossfield, A. V., McMahon, D. J., Fernando, J., Omeragic, B., Majeed, R., Agarwal, S., Sroga, G. E., Wang, B., Vashishth, D., & Rubin, M. R. (2025). The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae700

Vancouver

Brossfield AV, McMahon DJ, Fernando J, Omeragic B, Majeed R, Agarwal S, et al. The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae700

BibTeX
@article{Brossfield2025,
  author = {Brossfield, Aiden V and McMahon, Donald J and Fernando, Jason and Omeragic, Beatriz and Majeed, Rukshana and Agarwal, Sanchita and Sroga, Grazyna E and Wang, Bowen and Vashishth, Deepak and Rubin, Mishaela R},
  title = {The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae700}
}
Kostenlos starten →